JSPR
JSPR clinical trials: Jasper Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Jasper Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
JSPR on the catalyst calendar · JSPR registry changes
- Primary completion Jun 13, 2023ActualPhase 1NCT04429191JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationJasper Therapeutics, Inc. · MYELODYSPLASTIC SYNDROME; MDSCompletedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2026ActualPhase 2NCT06736262A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From...Jasper Therapeutics, Inc. · Urticaria ChronicTerminatedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2026ActualPhase 1/Phase 2NCT06162728Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With...Jasper Therapeutics, Inc. · Chronic Spontaneous UrticariaCompletedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2025ActualPhase 1/Phase 2NCT06353971A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients...Jasper Therapeutics, Inc. · Chronic Inducible UrticariaTerminatedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2025ActualPhase 1NCT06592768A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With...Jasper Therapeutics, Inc. · Allergic AsthmaTerminatedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2025ActualPhase 1/Phase 2NCT02963064JSP191 Antibody Targeting Conditioning in SCID PatientsJasper Therapeutics, Inc. · SCIDTerminatedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 21, 2024ActualPhase 1NCT05903274JSP191 (briquilimab) in Subjects with LR-MDSJasper Therapeutics, Inc. · Lower-risk Myelodysplastic SyndromeTerminatedJSPRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner